Bloomberg
Why J&J Raised Its 2023 Sales Forecast
Johnson & Johnson CFO Joseph Wolk explains why the company raised its 2023 sales forecast. He speaks with Guy Johnson and Alix Steel on "Bloomberg Markets."
Bloomberg
Novo Nordisk Halts Ozempic Study
Novo Nordisk is halting a study which looked at the impact of its blockbuster Ozempic drug on kidney failure after it showed effectiveness surprisingly early. Ed Ludlow reports.
Follow Bloomberg for business news & analysis,...
Press Association
Starmer welcomes UK return to EU Horizon science programme
Pool clip with Labour leader Sir Keir Starmer following a visit to AstraZeneca in Macclesfield. He discusses the UK's re-entry to the Horizon programme, the manhunt for Daniel Khalife and the upcoming Tamworth by-election
Press Association
Labour leader visits AstraZeneca laboratory
Labour leader Sir Keir Starmer visits AstraZeneca's cancer drug development training centre, sterilising hub and laboratories during a visit to AstraZeneca in Macclesfield.
Bloomberg
Biden Targets J&J, Bristol Drugs for Medicare Price Cuts
The Biden administration says 10 prescription drugs will be subject to price negotiations with Medicare. The White House says some prices could be cut in half. Bloomberg's John Tozzi reports.
Follow Bloomberg for business news &...
Bloomberg
J&J Done With Outlook 'Qualifiers' After Earnings Beat, CFO Says
Johnson & Johnson CFO Joseph Wolk discusses second-quarter performance, new products, and ongoing litigation over talc cancer claims on "Bloomberg Markets."
Bloomberg
China Urges Japan to Refrain From Joining US Chip Curbs
China's foreign minister has urged Japan to refrain from supporting US efforts to suppress the Chinese semiconductor industry. And Japan's foreign minister has urged his Chinese counterpart to quickly release an employee of Japanese...
Bloomberg
Dan Loebs Third Point Takes Aim at Amgen Break Up
Oct. 22 -- Bloomberg's Betty Liu reports on today's top news stories on In The Loop.
Bloomberg
It Will Take Years for Life to Get Back to Normal
Feb.08 -- The new Bloomberg Vaccine Tracker shows how long it will take states and countries to vaccinate 75% of their populations, which could then mean we're getting life back to normal.
Bloomberg
TV Networks Tackle Declining Ad Sales
Jul.12 -- TV networks including ESPN are bracing for a drop in advertising revenue for football games in the coming season, which could drag down sales growth for sports broadcasts overall, advertising and television executives say....
Curated Video
In Real Life: DIY Pharma
Newsy's original documentary series In Real Life brings us a firsthand look at the world of DIY pharmaceuticals.
Bloomberg
CVS CEO Merlo on Aetna Integration, Retail Strategy, Drug Pricing
Jan.14 -- CVS Health Corp. Chief Executive Officer Larry Merlo discusses the integration of acquisition Aetna Inc., brick and mortar retail strategy, and drug pricing transparency for consumers. He speaks with Bloomberg's Taylor Riggs on...
Bloomberg
Ascletis Pharma CEO on IPO Performance, New Drugs, Revenue Targets
Jan.17 -- Jason Wu, chairman and chief executive officer at Ascletis Pharma, discusses the company's performance since the IPO, their new drugs coming to market, competition in the industry, regulatory approvals, drug prices, revenue...
Bloomberg
Biden Begins 100-Day Review of Critical U.S. Supply Chains
Jun.08 -- President Joe Biden is looking to secure critical U.S. supply chains, ranging from medicine to microchips. The White House released a 250-page report Tuesday with assessments and a list of recommendations. Council of Economic...
Bloomberg
India Said to Block Fosun's $1.3B Gland Takeover
Jul.31 -- The Shanghai Fosun Pharmaceutical Group has been chasing the Indian drug maker Gland and offering $1.3B as a deal. However, Bloomberg has been told the Modi government will block it. Bloomberg's Ben Scent reports on "Bloomberg...
Curated Video
How Coronavirus Could Slow Down The U.S. Drug Supply
The United States relies on overseas factories for some of the key ingredients of vital medications, and shortages could impact medication supplies.
Bloomberg
Sage CEO Planning to Launch New Postpartum Drug in 2019
Jan.07 -- Sage Therapeutics Chief Executive Officer Jeff Jonas discusses the biotechnology company’s experimental antidepressant drug with Bloomberg's Taylor Riggs on "Bloomberg Markets: European Close."
Bloomberg
Sen. Grassley on Drug Pricing, Debt Ceiling, Presidential Power
Feb.26 -- Senator Chuck Grassley, chairman of the Senate Finance Committee and a Republican from Iowa, discusses bills aimed at reducing prescription drug prices ahead of a hearing with pharmaceutical executives, raising the debt...
Bloomberg
J&J 1Q Pharmaceutical Sales Help Overcome Pessimistic Forecast
Apr.16 -- Joseph Wolk, chief financial officer at Johnson & Johnson, discusses the company’s first-quarter results. He speaks on "Bloomberg Daybreak: Americas."
Bloomberg
J&J CFO on Earnings, Immunology Portfolio and Pricing Pressure
Jan.22 -- Joseph Wolk, Johnson & Johnson chief financial officer, discusses the company's fourth-quarter results, drug portfolio plans and industry pricing pressure with Bloomberg's David Westin on "Balance of Power."
Bloomberg
Eli Lilly Antibody Drug Will Reduce Hospitalizations: CEO
Nov.10 -- Eli Lilly & Co. Chairman and Chief Executive Officer David Ricks discusses the drugmaker's Covid-19 antibody therapy bamlanivimab, which was recently granted an emergency-use authorization by the U.S. Food and Drug...
Bloomberg
DFC Chief Boehler Reacts to Probe Into Kodak Loan
Aug.14 -- Adam Boehler, U.S. International Development Finance Corp. chief executive officer, comments on Congress and the Securities and Exchange Commission investigating the federal agency's $765 million loan to Eastman Kodak Co. and...
Bloomberg
RemeGen CEO on H.K. IPO, Strategy, Drugs in Pipeline
Nov.08 -- Fang Jianmin, co-founder and chief executive officer of RemeGen Co., discusses the Chinese biotechnology company's initial public offering, strategy, and the drugs in its pipeline. RemeGen jumped more than 30 percent on its...
Bloomberg
Eli Lilly CEO on 1Q Results, Drug Pricing, Pharma Margins
Apr.30 -- Dave Ricks, chairman and chief executive officer at Eli Lilly, discusses first-quarter results, the impact of drug pricing, and growing pharmaceutical business margins. He speaks on "Bloomberg Daybreak: Americas."